Announcements Trials

Browse Landscape

Phase

Phase 2 5 Phase 1 2 Phase EARLY_PHASE1 1 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 18 Parkinson Disease 4, Autosomal Dominant Lewy Body 6 Breast Neoplasms 6 Metastatic Castration-resistant Prostate Cancer 3 Fallopian Tube Neoplasms 3 Triple Negative Breast Neoplasms 2 Neoplasm Metastasis 2 Endometrial Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Carcinoma 2 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Prostatic Neoplasms 1 Peritoneal Neoplasms 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Neoplasms 1 Lung Neoplasms 1 Hematologic Neoplasms 1 HER2-ve Metastatic Breast Cancer 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Doxorubicin 25 Ifosfamide 22 Radiotherapy 17 Etoposide 11 Vincristine 10 Cyclophosphamide 10 Filgrastim 8 Dactinomycin 8 Trabectedin 7 Chemotherapy, Adjuvant 5 pazopanib 4 Cisplatin 4 Topotecan 3 Radiation 3 Neoadjuvant Therapy 3 Irinotecan 3 Granulocyte Colony-Stimulating Factor 3 Dacarbazine 3 sargramostim 2 etoposide phosphate 2 eribulin 2 Observation 2 Methotrexate 2 Mesna 2 Imatinib Mesylate 2 Gemcitabine 2 Epirubicin 2 Docetaxel 2 Dexrazoxane 2 Carboplatin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Sarcoma × olaparib × Clear all

NCT03784014 2026-04-29

MULTISARC

Institut National de la Santé Et de la Recherche Médicale, France

Phase 3 Completed

Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡